NextCure Statistics
Total Valuation
NextCure has a market cap or net worth of $27.37 million. The enterprise value is $11.95 million.
| Market Cap | 27.37M |
| Enterprise Value | 11.95M |
Important Dates
The last earnings date was Tuesday, November 10, 2026, after market close.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NextCure has 4.58 million shares outstanding. The number of shares has increased by 104.07% in one year.
| Current Share Class | 4.58M |
| Shares Outstanding | 4.58M |
| Shares Change (YoY) | +104.07% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 1.02% |
| Owned by Institutions (%) | 36.95% |
| Float | 2.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.00 |
| P/TBV Ratio | 2.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.47, with a Debt / Equity ratio of 0.38.
| Current Ratio | 3.47 |
| Quick Ratio | 3.15 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -204.56% and return on invested capital (ROIC) is -105.90%.
| Return on Equity (ROE) | -204.56% |
| Return on Assets (ROA) | -69.02% |
| Return on Invested Capital (ROIC) | -105.90% |
| Return on Capital Employed (ROCE) | -239.55% |
| Weighted Average Cost of Capital (WACC) | 9.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.02M |
| Employee Count | 40 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.65% in the last 52 weeks. The beta is 1.20, so NextCure's price volatility has been higher than the market average.
| Beta (5Y) | 1.20 |
| 52-Week Price Change | -29.65% |
| 50-Day Moving Average | 6.04 |
| 200-Day Moving Average | 7.58 |
| Relative Strength Index (RSI) | 51.33 |
| Average Volume (20 Days) | 60,285 |
Short Selling Information
The latest short interest is 220,966, so 4.83% of the outstanding shares have been sold short.
| Short Interest | 220,966 |
| Short Previous Month | 213,309 |
| Short % of Shares Out | 4.83% |
| Short % of Float | 7.57% |
| Short Ratio (days to cover) | 2.24 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -38.84M |
| Pretax Income | -40.97M |
| Net Income | -40.97M |
| EBITDA | -37.66M |
| EBIT | -38.84M |
| Earnings Per Share (EPS) | -$8.27 |
Balance Sheet
The company has $20.09 million in cash and $4.67 million in debt, with a net cash position of $15.42 million or $3.37 per share.
| Cash & Cash Equivalents | 20.09M |
| Total Debt | 4.67M |
| Net Cash | 15.42M |
| Net Cash Per Share | $3.37 |
| Equity (Book Value) | 12.15M |
| Book Value Per Share | 2.99 |
| Working Capital | 15.84M |
Cash Flow
In the last 12 months, operating cash flow was -$36.98 million and capital expenditures $26.71 million, giving a free cash flow of -$36.98 million.
| Operating Cash Flow | -36.98M |
| Capital Expenditures | 26.71M |
| Depreciation & Amortization | 1.18M |
| Net Borrowing | n/a |
| Free Cash Flow | -36.98M |
| FCF Per Share | -$8.08 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NextCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -104.07% |
| Shareholder Yield | -104.07% |
| Earnings Yield | -138.24% |
| FCF Yield | -140.27% |
Analyst Forecast
The average price target for NextCure is $20.00, which is 234.45% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.00 |
| Price Target Difference | 234.45% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jul 14, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |